Skip to main content
An official website of the United States government
Government Funding Lapse
Because of a lapse in government funding, the information on this website may not be up to date, transactions submitted via the website may not be processed, and the agency may not be able to respond to inquiries until appropriations are enacted.

The NIH Clinical Center (the research hospital of NIH) is open. For more details about its operating status, please visit cc.nih.gov.

Updates regarding government operating status and resumption of normal operations can be found at opm.gov.

allogeneic CMV antigen-specific CD4+/CD8+ T lymphocytes

A population of allogeneic T lymphocytes specifically reactive to cytomegalovirus (CMV) with potential antiviral activity. Allogeneic CMV antigen-specific T cells are prepared via ex vivo stimulation of donor-derived peripheral blood mononuclear cells (PBMCs) with major cytomegalovirus structural protein, pp65 (ppUL83). T cells that secrete interferon (IFN)-gamma in response to pp65 antigen exposure are selected and expanded for administration. Administration of the CMV antigen-specific CD4+ and CD8+T lymphocytes into hematopoietic stem cell transplant (HSCT) or immunocompromised patients infected with CMV may potentially reconstitute virus-specific responses, thereby controlling CMV infections
Check for active clinical trials using this agentView this agent in the NCI Thesaurus
Synonym:allogeneic CMV-specific antigen-selected T cells
allogeneic cytomegalovirus-specific CD4+ and CD8+ T cells
allogeneic cytomegalovirus-specific CD4+ and CD8+ T lymphocytes
Search NCI's Drug Dictionary
Please enter up to 30 characters for your search